

Jaime L. Chase +1 202 728 7096

jchase@cooley.com September 29, 2022

U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549

Attention: Brittany Ebbertt

Kathleen Collins Stephanie Sullivan

Re: Endava plc.

Amendment to Annual Report on Form 20-F (File No. 001-38607)

Filed on September 28, 2021

CIK 0001656081

## Ladies and Gentlemen:

On behalf of Endava plc (the "Company"), the following information is in response to comments received from the staff (the "Staff") of the Securities and Exchange Commission (the "Commission") by letter dated September 16, 2022 (the "Comment Letter") with respect to the Annual Report on Form20-F filed with the Commission on September 28, 2021 (the "2021 Annual Report").

For the convenience of the Staff, the numbering of the paragraph below corresponds to the numbering of the comment in the Comment Letter, the text of which we have incorporated into this response letter for convenience in italicized type and which is followed by the Company's response.

## Form 20-F for the fiscal year ended June 30, 2021

## **General**

1. We have reviewed your response to prior comment 1 and continue to believe that the Endava plc financial statements are materially deficient for any years that KPMG Audit SRL, a firm that is not registered with the Public Company Accounting Oversight Board ("PCAOB"), played a substantial role in the audit. Please correct the material deficiency in your audited financial statements to comply with Section 102(a) of the Sarbanes-Oxley Act and PCAOB Rule 2100 that require any accounting firm playing a substantial role in the audit of an issuer be registered with the PCAOB.

The Company acknowledges the Staff's comment and confirms that the Company's auditor will correct the deficiency in the audit of the Company's financial statements to comply with the provisions set forth above and such corrections will be reflected in the Company's Annual Report on Form 20-F for the year ended June 30, 2022.

Cooley LLP 1299 Pennsylvania Avenue, NW, Suite 700 Washington, DC 20004-2400 t: (202) 842-7800 f: (202) 842-7899 cooley.com



September 29, 2022 Page Two

\* \* \*

Please contact me at (202) 728-7096, Eric Jensen at (650) 843-5049 or John McKenna at (650) 843-5059 with any questions or further comments regarding our responses to the Staff's comments.

Sincerely,

/s/ Jaime L. Chase

Jaime L. Chase

ce: John Cotterell, Endava plc
Mark Thurston, Endava plc
Rohit Bhoothalingam, Endava plc
Eric Jensen, Cooley LLP
John McKenna, Cooley LLP

Cooley LLP 1299 Pennsylvania Avenue, NW, Suite 700 Washington, DC 20004-2400 t: (202) 842-7800 f: (202) 842-7899 cooley.com